Press release
Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting
Presentations highlight potential of losmapimod to slow or stop progression of FSHD Company on track to initiate Phase 3 REACH trial in 2Q 2022 CAMBRIDGE,
About this update from Fulcrum Therapeutics, Inc.
[{"type":"text","content":"Presentations highlight potential of losmapimod to slow or stop progression of FSHD Company on track to initiate Phase 3 REACH trial in 2Q 2022 CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple oral and poster presentations on losmapimod for facioscapulohumeral muscular dystrophy (FSHD) at the American Academy of Neurology’s Annual Meeting, taking place April 2-7 in Seattle, WA. These presentations highlight clinical data supporting the potential of losmapimod as well as the design of the Phase 3 REACH trial of losmapimod in FSHD. “FSHD is a progressive, relentless, and debilitating disease for which there are no approved therapies,” said Christopher Morabito, MD, Fulcrum’s chief medical officer. “The clinical data being presented at AAN demonstrate losmapimod’s potential to slow or stop disease progression, while providing important insights into optimal measures of disease progression in FSHD. As we prepare to begin enrolling patients in our Phase 3 REACH trial this quarter, we remain focused on serving the FSHD community by working to bring a much-needed therapy to patients.” Oral Presentations:The following presentations will take place during the S23 – Therapeutics for Muscle Diseases Scientific Platform Session A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in Subjects with FSHD: ReDUX4 Date/Time: Tuesday, April 5th, 4:42pm – 4:54pm PDTPresenter: Christopher Morabito, MD—Fulcrum Therapeutics An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1 Date/Time: Tuesday, April 5th, 4:54pm – 5:06pm PDTPresenter: Jennifer Shoskes, PharmD —Fulcrum Therapeutics Whole Body MRI Quantitative muscle analysis to evaluate Efficacy of Losmapimod in a Phase 2 Placebo-Controlled Study in Subjects with FSHD (ReDUX4) Date/Time: Tuesday, April 5th, 5:06pm – 5:18pm PDTPresenter: Christopher Morabito, MD—Fulcrum Therapeutics Poster Presentations:The following poster will be available during the Poster Session 4 on Sunday, April 3rd from 8:00am to 9:00am PDT. Reachable Workspace to Evaluate Efficac...